These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 34151860)
1. Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients. Youssef P; Kim WS; Halliday GM; Lewis SJG; Dzamko N J Parkinsons Dis; 2021; 11(4):1761-1772. PubMed ID: 34151860 [TBL] [Abstract][Full Text] [Related]
2. Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson's disease. Lasseter HC; Provost AC; Chaby LE; Daskalakis NP; Haas M; Jeromin A Cytokine X; 2020 Jun; 2(2):100027. PubMed ID: 33604555 [TBL] [Abstract][Full Text] [Related]
3. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease. Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018 [TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson's Disease. Zou J; Guo Y; Wei L; Yu F; Yu B; Xu A Neurotherapeutics; 2020 Jul; 17(3):1104-1119. PubMed ID: 32236821 [TBL] [Abstract][Full Text] [Related]
6. Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson's Disease Patients. Nam D; Lee JY; Lee M; Kim J; Seol W; Son I; Ho DH J Parkinsons Dis; 2020; 10(3):981-991. PubMed ID: 32444560 [TBL] [Abstract][Full Text] [Related]
7. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease. Chen CH; Lee BC; Lin CH J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681 [TBL] [Abstract][Full Text] [Related]
8. Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. Yang SY; Chiu MJ; Lin CH; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH J Nanobiotechnology; 2016 Jun; 14(1):41. PubMed ID: 27278241 [TBL] [Abstract][Full Text] [Related]
9. A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease. Foulds PG; Diggle P; Mitchell JD; Parker A; Hasegawa M; Masuda-Suzukake M; Mann DM; Allsop D Sci Rep; 2013; 3():2540. PubMed ID: 23985836 [TBL] [Abstract][Full Text] [Related]
11. Plasma Total α-Synuclein and Neurofilament Light Chain: Clinical Validation for Discriminating Parkinson's Disease from Normal Control. Lin WC; Lu CH; Chiu PY; Yang SY Dement Geriatr Cogn Disord; 2020; 49(4):401-409. PubMed ID: 33242863 [TBL] [Abstract][Full Text] [Related]
12. Plasma α-synuclein predicts cognitive decline in Parkinson's disease. Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072 [TBL] [Abstract][Full Text] [Related]
13. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression. Niu M; Li Y; Li G; Zhou L; Luo N; Yao M; Kang W; Liu J Eur J Neurol; 2020 Jun; 27(6):967-974. PubMed ID: 32150777 [TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein in peripheral body fluid as a biomarker for Parkinson's disease. Shu H; Zhang P; Gu L Acta Neurol Belg; 2024 Jun; 124(3):831-842. PubMed ID: 38170418 [TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms. Petricca L; Chiki N; Hanna-El-Daher L; Aeschbach L; Burai R; Stoops E; Fares MB; Lashuel HA J Parkinsons Dis; 2022; 12(5):1449-1462. PubMed ID: 35527570 [TBL] [Abstract][Full Text] [Related]
16. Association of Misfolded α-Synuclein Derived from Neuronal Exosomes in Blood with Parkinson's Disease Diagnosis and Duration. Schaeffer E; Kluge A; Schulte C; Deuschle C; Bunk J; Welzel J; Maetzler W; Berg D J Parkinsons Dis; 2024; 14(4):667-679. PubMed ID: 38669557 [TBL] [Abstract][Full Text] [Related]
17. Potential Exosome Biomarkers for Parkinson's Disease Diagnosis: A Systematic Review and Meta-Analysis. Kim KY; Shin KY; Chang KA Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791346 [TBL] [Abstract][Full Text] [Related]
18. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Shi M; Zabetian CP; Hancock AM; Ginghina C; Hong Z; Yearout D; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Leverenz JB; Zhang J Neurosci Lett; 2010 Aug; 480(1):78-82. PubMed ID: 20540987 [TBL] [Abstract][Full Text] [Related]
19. Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease. Si X; Tian J; Chen Y; Yan Y; Pu J; Zhang B Neuroscience; 2019 Aug; 413():308-316. PubMed ID: 31102760 [TBL] [Abstract][Full Text] [Related]
20. Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease. Emmanouilidou E; Papagiannakis N; Kouloulia S; Galaziou A; Antonellou R; Papadimitriou D; Athanasiadou A; Bozi M; Koros C; Maniati M; Vekrellis K; Ioannou PC; Stefanis L Parkinsonism Relat Disord; 2020 Apr; 73():35-40. PubMed ID: 32234683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]